Marshall Wace
TVRD

Marshall Wace’s Tvardi Therapeutics TVRD Stock Holding History

Marshall Wace’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,980
Closed -$583K – 3528
2025
Q2 		$583K Buy
+24,980
New +$591K ﹤0.01% 2092
2023
Q3 		– Sell
-3,698
Closed -$377K – 2775
2023
Q2 		$377K Buy
+3,698
New +$509K ﹤0.01% 2077
2021
Q2 		– Sell
-1,781
Closed -$1.39M – 3185
2021
Q1 		$1.39M Buy
+1,781
New +$1.22M 0.01% 1499
2020
Q4 		– Sell
-432
Closed -$198K – 2251
2020
Q3 		$198K Sell
432
-1,458
-77% -$847K ﹤0.01% 1458
2020
Q2 		$1.16M Buy
+1,890
New +$1.04M 0.01% 954
2019
Q1 		– Sell
-9,167
Closed -$4.29M – 2105
2018
Q4 		$4.29M Sell
9,167
-3,342
-27% -$2.16M 0.04% 492
2018
Q3 		$10.8M Buy
12,509
+2,817
+29% +$2.03M 0.09% 288
2018
Q2 		$6.68M Buy
+9,692
New +$4.93M 0.1% 239

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's TVRD Position: Q3 2025 in Review

Marshall Wace sold out of Tvardi Therapeutics (TVRD) in Q3 2025, closing a stake of 24,980 shares — an estimated $583K sold.

Marshall Wace first reported a position in TVRD in Q2 2018 and held it in 8 quarters. The position peaked at $10.8M in Q3 2018. 73 funds tracked by Wall St. Rank hold TVRD as of Q3 2025.

  • Marshall Wace reported no remaining Tvardi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Marshall Wace sold 24,980 Tvardi Therapeutics shares in Q3 2025, an estimated $583K.
  • Marshall Wace first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 8 quarters.
  • Marshall Wace's Tvardi Therapeutics position peaked at $10.8M in Q3 2018.
  • 73 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.